Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a Healthcare company (Biotechnology) with a market capitalization of $364M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Lyell Immunopharma, Inc. had a Maz Rating of 2.18 out of 5 (C, Hold), ranked against the other companies in its sector. Its strongest factor then was Growth (4.25), above most of its sector; its weakest was Profitability (1.37), among the weakest in its sector. The other factors: Valuation 3.07 (valued in line with its sector); Financial Health 2.77 (around the middle of its sector); Momentum 2.33 (below most of its sector). The current rating is for members: log in to see it.
At $14.86, Lyell Immunopharma, Inc. trades at 24505.1x sales and 1.9x book value. Over the last twelve months it generated about $14860 of revenue and a net loss of $382M. It runs a gross margin of -15466.7%, an operating margin of -1044686.7% and a net margin of -1701066.7%. It shows return on equity of -107.6%, return on invested capital of -68.9% and a free cash flow yield of -38.5%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 4.02. Over the past 52 weeks the share price ranged from $7.20 to $45.00, with a beta of -0.07.
Lyell Immunopharma, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 3 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.